Last $1.47 USD
Change Today -0.03 / -2.00%
Volume 2.7M
SNSS On Other Exchanges
Symbol
Exchange
NASDAQ CM
Frankfurt
As of 8:10 PM 10/21/14 All times are local (Market data is delayed by at least 15 minutes).

Audit Committee* - sunesis pharmaceuticals inc (SNSS)

Name (Connections)Board RelationshipsTitleKey Developments
Matthew Fust 37 RelationshipsIndependent Director, Chairman of Audit Committee and Member of Compensation CommitteeSunesis Pharmaceuticals Inc. announced delayed annual 10-K filing
04/1/09
David Stump M.D. 18 RelationshipsIndependent Director and Member of Audit Committee 
Helen Kim MBA 25 RelationshipsDirector and Member of Audit Committee 

Compensation Committee* - sunesis pharmaceuticals inc (SNSS)

Name (Connections)Board RelationshipsTitle
Stefano Carchedi 28 RelationshipsDirector and Member of Compensation Committee
Matthew Fust 37 RelationshipsIndependent Director, Chairman of Audit Committee and Member of Compensation Committee
Dayton Misfeldt 25 RelationshipsDirector, Chairman of Compensation Committee and Member of Nominating & Corporate Governance Committee
SNSS Compensation vs. Industry
469.9K
366.1K
Chief Executive Officer
378.8K
267.9K
Chief Financial Officer
Share price activity for SUNESIS PHARMACEUTICALS INC (SNSS)
52 Week Price Performance
SNSS
Industry Average

Nominating Committee* - sunesis pharmaceuticals inc (SNSS)

Name (Connections)Board RelationshipsTitleKey Developments
Homer Pearce Ph.D. 76 RelationshipsDirector and Chairman of Nominating & Corporate Governance CommitteeSunesis Pharmaceuticals, Inc. Appoints Joseph I. DePinto as Executive Vice President and Chief Commercial Officer
02/10/14
Dayton Misfeldt 25 RelationshipsDirector, Chairman of Compensation Committee and Member of Nominating & Corporate Governance CommitteeSunesis Pharmaceuticals, Inc. Announces Resignation of Edward Hurwitz as a Director
09/23/13

Corporate Governance Committee* - sunesis pharmaceuticals inc (SNSS)

Name (Connections)Board RelationshipsTitle
Dayton Misfeldt 25 RelationshipsDirector and Member of Compensation Committee
Homer Pearce Ph.D. 76 RelationshipsIndependent Director, Chairman of Audit Committee and Member of Compensation Committee
SNSS and Competitor
Insiders vs. External
Board
11%
89%
Sunesis Pharmaceuticals, Inc.
9%
91%
POZEN Inc.
9%
91%
NeurogesX, Inc.
Insiders
External Board Members
*Data is at least as current as the most recent Definitive Proxy.
 

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
SNSS:US $1.47 USD -0.03

SNSS Competitors

Market data is delayed at least 15 minutes.

Company Last Change
NeurogesX Inc $0.0034 USD -0.0046
POZEN Inc $8.27 USD +0.19
View Industry Companies
 

Industry Analysis

SNSS

Industry Average

Valuation SNSS Industry Range
Price/Earnings NM Not Meaningful
Price/Sales 10.9x
Price/Book 5.5x
Price/Cash Flow NM Not Meaningful
TEV/Sales 1.8x
 | 

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact SUNESIS PHARMACEUTICALS INC, please visit . Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.